Skip to content

Study · Randomized controlled trial · n = 46 · 2021

8 results

Efficacy and safety of exenatide as add-on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double-blind trial.

Joubert M, Opigez V, Pavlikova B, Peyro Saint Paul L, Jeandidier N, Briant AR, Parienti JJ, Reznik Y

Diabetes, obesity & metabolism30 Oct 2020Cited by 9 (Europe PMC)

PMID33043591 (opens in a new tab)DOI10.1111/dom.14225 (opens in a new tab)PepBankPUB-33043591
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with T2D on intensive insulin, exenatide lowered HbA1c more than placebo.

    In plain wordsExenatide lowered average blood sugar more than placebo in patients with diabetes receiving intensive insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change
    Study

    n = 46

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg BID · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.62%
    exenatide
    HbA1c change
    0.08%
    placebo
    HbA1c difference
    −0.7%
    exenatide versus placebo

    Source sentences

    Summary
    At 6 months, the change in HbA1c was -0.62% ± 0.94% and 0.08% ± 0.81% in the exenatide and placebo groups, respectively (difference, -0.70%; 95% CI [-1.24%; -0.15%], P = .014);
    3 context sentences
    Summary · context
    A phase 2/3, multicentre, randomized, parallel-group, double-blind, placebo-controlled, 6-month trial was conducted.
    Summary · context
    Patients were randomized to receive subcutaneous (SC) injections of exenatide (10 μg BID) or matched placebo.
    Summary · context
    A total of 46 patients with T2D and elevated HbA1c were randomized (42% of the planned sample size): exenatide (n = 28) and placebo (n = 18).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with T2D on intensive insulin, exenatide reduced body weight versus placebo.

    In plain wordsExenatide reduced weight compared with placebo in patients with diabetes receiving intensive insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight change
    Study

    n = 46

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 μg BID · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Weight change
    −2.55 kg
    exenatide
    Weight change
    1.29 kg
    placebo
    Weight difference
    −3.85 kg
    exenatide versus placebo

    Source sentences

    Summary
    body weight and body mass index decreased in the exenatide group (-2.55 ± 3.25 kg and -1.00 ± 1.31 kg/m2 ) and increased in the placebo group (1.29 ± 2.82 kg and 0.46 ± 1.16 kg/m2 ) (observed difference, -3.85 and -1.45, respectively, both P < .001);
    3 context sentences
    Summary · context
    A phase 2/3, multicentre, randomized, parallel-group, double-blind, placebo-controlled, 6-month trial was conducted.
    Summary · context
    Patients were randomized to receive subcutaneous (SC) injections of exenatide (10 μg BID) or matched placebo.
    Summary · context
    A total of 46 patients with T2D and elevated HbA1c were randomized (42% of the planned sample size): exenatide (n = 28) and placebo (n = 18).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with T2D on intensive insulin, exenatide reduced BMI versus placebo.

    In plain wordsExenatide reduced BMI compared with placebo in patients with diabetes receiving intensive insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBMI change
    Study

    n = 46

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 μg BID · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    BMI change
    −1 kg/m2
    exenatide
    BMI change
    0.46 kg/m2
    placebo
    BMI difference
    −1.45 kg/m2
    exenatide versus placebo

    Source sentences

    Summary
    body weight and body mass index decreased in the exenatide group (-2.55 ± 3.25 kg and -1.00 ± 1.31 kg/m2 ) and increased in the placebo group (1.29 ± 2.82 kg and 0.46 ± 1.16 kg/m2 ) (observed difference, -3.85 and -1.45, respectively, both P < .001);
    3 context sentences
    Summary · context
    A phase 2/3, multicentre, randomized, parallel-group, double-blind, placebo-controlled, 6-month trial was conducted.
    Summary · context
    Patients were randomized to receive subcutaneous (SC) injections of exenatide (10 μg BID) or matched placebo.
    Summary · context
    A total of 46 patients with T2D and elevated HbA1c were randomized (42% of the planned sample size): exenatide (n = 28) and placebo (n = 18).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with T2D on intensive insulin, postdinner capillary glucose was lower with exenatide than placebo.

    In plain wordsExenatide lowered blood sugar after dinner compared with placebo in patients with diabetes receiving intensive insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostdinner capillary blood glucose
    Study

    n = 46

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg BID · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Postdinner glucose
    162.4 mg/dL
    exenatide
    Postdinner glucose
    259.1 mg/dL
    placebo
    Glucose difference
    −96.7 mg/dL
    exenatide versus placebo

    Source sentences

    Summary
    the postdinner capillary blood glucose value was lower in the exenatide group compared with the placebo group (162.4 ± 80.5 vs. 259.1 ± 94.4 mg/dL, respectively; observed difference, -96.7, P < .01).
    3 context sentences
    Summary · context
    A phase 2/3, multicentre, randomized, parallel-group, double-blind, placebo-controlled, 6-month trial was conducted.
    Summary · context
    Patients were randomized to receive subcutaneous (SC) injections of exenatide (10 μg BID) or matched placebo.
    Summary · context
    A total of 46 patients with T2D and elevated HbA1c were randomized (42% of the planned sample size): exenatide (n = 28) and placebo (n = 18).
  5. 05HumanRandomized controlled trialSafety outcome

    In patients with T2D on intensive insulin, hypoglycemic risk did not differ between exenatide and placebo.

    In plain wordsLow blood sugar risk did not differ between exenatide and placebo during intensive insulin treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHypoglycemic risk
    Study

    n = 46

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    10 μg BID · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Hypoglycaemic risk, quality of life and overall safety were not different between the groups, apart from the expected occurrence of digestive effects in the exenatide group.
    3 context sentences
    Summary · context
    A phase 2/3, multicentre, randomized, parallel-group, double-blind, placebo-controlled, 6-month trial was conducted.
    Summary · context
    Patients were randomized to receive subcutaneous (SC) injections of exenatide (10 μg BID) or matched placebo.
    Summary · context
    A total of 46 patients with T2D and elevated HbA1c were randomized (42% of the planned sample size): exenatide (n = 28) and placebo (n = 18).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with T2D on intensive insulin, quality of life did not differ between exenatide and placebo.

    In plain wordsQuality of life did not differ between exenatide and placebo during intensive insulin treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeQuality of life
    Study

    n = 46

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    10 μg BID · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Hypoglycaemic risk, quality of life and overall safety were not different between the groups, apart from the expected occurrence of digestive effects in the exenatide group.
    3 context sentences
    Summary · context
    A phase 2/3, multicentre, randomized, parallel-group, double-blind, placebo-controlled, 6-month trial was conducted.
    Summary · context
    Patients were randomized to receive subcutaneous (SC) injections of exenatide (10 μg BID) or matched placebo.
    Summary · context
    A total of 46 patients with T2D and elevated HbA1c were randomized (42% of the planned sample size): exenatide (n = 28) and placebo (n = 18).
  7. 07HumanRandomized controlled trialSafety outcome

    In patients with T2D on intensive insulin, overall safety was similar between exenatide and placebo apart from digestive effects.

    In plain wordsOverall safety was similar between exenatide and placebo, except for digestive effects.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeOverall safety
    Study

    n = 46

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    10 μg BID · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Hypoglycaemic risk, quality of life and overall safety were not different between the groups, apart from the expected occurrence of digestive effects in the exenatide group.
    3 context sentences
    Summary · context
    A phase 2/3, multicentre, randomized, parallel-group, double-blind, placebo-controlled, 6-month trial was conducted.
    Summary · context
    Patients were randomized to receive subcutaneous (SC) injections of exenatide (10 μg BID) or matched placebo.
    Summary · context
    A total of 46 patients with T2D and elevated HbA1c were randomized (42% of the planned sample size): exenatide (n = 28) and placebo (n = 18).
  8. 08HumanRandomized controlled trialSafety outcome

    In patients with T2D on intensive insulin, digestive effects occurred in the exenatide group.

    In plain wordsDigestive side effects occurred in patients receiving exenatide with intensive insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedDigestive effects
    Study

    n = 28

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    10 μg BID · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Hypoglycaemic risk, quality of life and overall safety were not different between the groups, apart from the expected occurrence of digestive effects in the exenatide group.
    3 context sentences
    Summary · context
    A phase 2/3, multicentre, randomized, parallel-group, double-blind, placebo-controlled, 6-month trial was conducted.
    Summary · context
    Patients were randomized to receive subcutaneous (SC) injections of exenatide (10 μg BID) or matched placebo.
    Summary · context
    A total of 46 patients with T2D and elevated HbA1c were randomized (42% of the planned sample size): exenatide (n = 28) and placebo (n = 18).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.